I think there is an interesting possibility of a buyout. When you factor in the accumulated losses that an acquiring company could claim, the volume of genetic data, the AKIP discovery platform, the two orphan drug programs, the on going phase 3 trail, and the IND's to be filed ARQL has a lot to offer.